FDA OKs Breckenridge's ANDA for rizatriptan benzoate

01/2/2013 | Pharmaceutical Business Review Online

Breckenridge Pharmaceutical's abbreviated new-drug application for rizatriptan benzoate tablets received FDA approval. The tablet, manufactured by Natco Pharma, is the bioequivalent of Merck & Co.'s prescription migraine drug Maxalt.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ